

CERTIFICATE OF MAILING (37 CFR 1.8)

Date of Deposit with U.S. Postal Service: August 2, 2002

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.

Julie K. Lyons, Legal Assistant

Name of Person Mailing Paper

Julie K. Lyons
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Examiner : Unknown
Applicant(s) : ME Schnute
Serial No. : 09/875,432
Filed : June 5, 2001
For : 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS

Commissioner of Patents and Trademarks
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL
UNDER 37 CFR 1.97 AND 1.98**

Sir:

Information Disclosed. The information disclosed consists of the following:

- [x] **Form PL-1449.** Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.
- [x] At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:
- [] contained in the above-captioned specification as filed;
[] provided in a communication enclosed with this paper;
[x] provided in the International Search Report enclosed with this paper; and/or
[] not necessary as all of the references cited are in the English language.

- [] ***Disclosure from Predecessor Application.*** Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed , the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).


Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:

- [x] ***§1.97(b),*** as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- [] ***§1.97(c),*** as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311.
Consideration of this information disclosure statement at this time is requested for the reason checked below:
- [] **Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- [] A statement as specified in 37 CFR 1.97(e) below.
- [] ***§1.97(d),*** as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by:
- [] **Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- [] A petition requesting consideration of the information disclosure statement; and
- [] A statement as specified in 37 CFR 1.97 (e) below.
- [] ***§1.97(e),*** this is a **supplemental information disclosure statement.** A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that

- [] Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.
- [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,



Lucy X. Yang, Attorney
Registration No. 40,259

Date: Aug 21, 2002

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-9536 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

Attachment(s)

- [x] Form 1449 with copies of reference(s)
[] Form 1449 from predecessor application (no references)
[] Communication providing concise explanation of relevance
[x] International Search Report

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>			Atty. Docket No. 00223.US1		Serial No. 09/875,432	
			Applicant ME Schnute			
			Filing Date June 5, 2001			Group 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	4,786,664	November 22, 1988	EJ Glamkowski, Et. Al.	514	312	Nov. 27, 1987
	AB	4,956,465	September 11, 1990	Schriewer, Et. Al.	546	156	October 3, 1988
	AC	4,959,363	September 25, 1990	MP Wentland	514	235.2	June 23, 1989
	AD	5,175,151	December 29, 1992	Adriano Afonso, Et. Al.	514	63	Feb. 5, 1992
	AE	5,328,887	July 12, 1994	Wilhelmus Janssens	503	227	August 26, 1992
	AF	5,622,967	April 22, 1997	RE Dolle, Et. Al.	514	233	May 25, 1995
	AG	5,753,666	May 19, 1998	SC Beasley, Et. Al.	514	258	August 2, 1996
	AH	5,891,878	April 6, 1999	SC Beasley, Et. Al.	514	247	August 2, 1996
	AI	6,015,789	Jan. 18, 2000	Nobuhiro Suzuki, Et. Al.	514	15	April 30, 1996

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ	WO96/16046	May 30, 1996	WIPO	C07D	239/49	X	
	AK	WO97/04775	February 13, 1997	WIPO	A61K	31/435	X	
	AL	WO98/23608	June 4, 1998	WIPO	C07D	401/12	X	
	AM	WO99/32450	July 1, 1999	WIPO	C07D	215/56	X	
	AN	EP 370686 B1	November 15, 1989	Europe	C07D	229/56	X	
	AO	EP 612731 A1	January 27, 1994	Europe	C07D	233/54		X
	AP	EP 945435 A1	August 29, 1999	Europe	C07D	215/56	X	
	AQ	JP02124871	May 14, 1990	Japan	C07D	213/81		X
	AR	JP44012143 (Abstract)	July 9, 1966	Japan			X	
	AS	GB1,191,443	May 13, 1970	Great Britian	C07D	99/00	X	
	AT	GB2,236,751 A	April 17, 1991	Great Britian	C07D	451/00	X	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AV	Wentland, Mark P. et al., <u>Drug Design and Discovery</u> . "Antiviral Properties of 3-Quinolinecarboxamides" A Series of Novel Non-Nucleoside Antiherpetic Agents". 1997, Vol 15, pp 25-38
AW	Wentland, Mark P. Et. Al., <u>Journal of Medicinal Chemistry</u> . "Cyclic Variations of 3-Quinolinecarboxamides and Effects on Antiherpetic Activity. 2541-2545, 38, 1995.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No.	Serial No.
		00223.US1	09/875,432
		Applicant	ME Schnute
Filing Date	June 5, 2001	Group 1614	
AX	Wentland, Mark P. Et. Al., <u>Journal of Medicinal Chemistry</u> . "3-Quinolinecarboxamides. A Series of Novel Orally-Active Antitherapeutic Agents. 1580-1596, 36, 1993.		
AY			
AZ			
BA			
Examiner		Date Considered	